Udayavni Special

Zydus Cadila says ‘Positive Results’ from Phase 2 studies of Covid-19 drug Desidustat in Mexico


PTI, Jan 25, 2021, 1:05 PM IST

Drug firm Zydus Cadila on Monday said it has received positive results from phase 2(b) studies of Desidustat in COVID-19 patients conducted in Mexico. In June 2020, Zydus Cadila had received approval from Mexico’s regulatory authority Cofepris to test one of its lead research candidate Desidustat in the management of COVID-19.

The company has received positive results from phase 2(b) studies of Desidustat in COVID-19 patients, Cadila Healthcare said in a regulatory filing. Zydus Cadila, which is part of Cadila Healthcare, said: ”Patients infected with COVID-19 have been reported to display signs of ’Hypoxia’ leading to organ failure and death despite the use of antivirals, anti-inflammatory drugs or ventilators… The phase 2(b) results of this study revealed that Desidustat treatment led to increased red blood cell production and improved oxygen delivery to tissues.

”None of the hospitalised patients required mechanical ventilator in the Desidustat arm, while 25 per cent of COVID-19 patients on the standard of care arm required mechanical ventilation.” Pankaj R Patel, Chairman, Zydus Group said, We are excited to report for the first time, this encouraging data of… Desidustat, showing the potential to help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients. ARDS is associated with high mortality rate and Zydus remains committed to further develop this novel therapy for patients suffering from ARDS.” Clinical and regulatory development of Desidustat in COVID-19 was executed in Mexico by Avant Sant Research Center S.A. de C.V., a leading Contract Research Organization (CRO) headquartered in Monterrey, Mexico, the company said.

Shares of Cadila Healthcare were trading 0.59 per cent higher at Rs 463 apiece on the BSE.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Udupi: Team of youth from Hejamadi build micro seaplane

TMC, others question 8-phase polls in Bengal; BJP welcomes EC decision

CM Yediyurappa launches ‘Namma Cargo’

NHAI daily toll collection through FASTag reaches record Rs 104 cr

K’taka COVID-19 update: 571 new cases, 642 discharges, 4 deaths on Feb 25

Karnataka objects to TN’s surplus Cauvery water claim, decides to fight legally

I accidentally became a cricketer, says Ashwin



Related Articles More

K’taka COVID-19 update: 571 new cases, 642 discharges, 4 deaths on Feb 25

India sent over 361 Lakh Anti-Covid vaccine doses to various Countries: MEA

Mandya-origin US Surgeon General nominee Vivek Murthy says his first and foremost priority is to turn COVID pandemic around

Karnataka adds 453 new COVID-19 cases, 7 deaths push toll to 12,316

Tie-up with Serum Institute of India key to mass production of COVID vaccines, say two pharma majors

MUST WATCH

Problem! in Cowin App

Listen to the story by Dr. Gururaj Karjagi on the concept of ‘Joy of Giving’- Part-3

This full-time construction worker makes caps from areca leaves in his spare time

Tea – Coffee | Reasons Not to Drink Too Much

HDK government has become Joker government: Yogeshwar

Latest Additions

Udupi: Team of youth from Hejamadi build micro seaplane

TMC, others question 8-phase polls in Bengal; BJP welcomes EC decision

CM Yediyurappa launches ‘Namma Cargo’

NHAI daily toll collection through FASTag reaches record Rs 104 cr

K’taka COVID-19 update: 571 new cases, 642 discharges, 4 deaths on Feb 25

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.